The European Medicines Agency has updated its 2009 guidance on the clinical investigation of medicines for Alzheimer’s disease to integrate requirements for development programs that start at earlier stages of the condition when it might even be possible to prevent the disease.
While currently available Alzheimer’s drugs only treat the disease’s symptoms, there is now a consensus that treatment options should be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?